Fc gamma receptor 3A polymorphism and risk for HIV-associated cryptococcal disease

mBio

Volumn 4, Issue 5, 2013, Pages

  Rohatgi, Soma ^a   Gohil, Shruti ^a,b   Kuniholm, Mark H ^a   Schultz, Hannah ^a   Dufaud, Chad ^a   Armour, Kathryn L ^c   Badri, Sheila ^d   Mailliard, Robbie B ^e   Pirofski, Liise Anne ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d Jr Hospital of Cook County   (United States)

^e UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; FC RECEPTOR IIA; FC RECEPTOR IIIA; UNCLASSIFIED DRUG;

ADULT; ALLELE; ANTIBODY DEPENDENT LYMPHOCYTOTOXICITY; ANTIGEN ANTIBODY COMPLEX; ARTICLE; BINDING AFFINITY; BISEXUAL MALE; CASE CONTROL STUDY; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CELL LOSS; COHORT ANALYSIS; COMPLEX FORMATION; CONTROLLED STUDY; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; CYTOTOXICITY; DISEASE ASSOCIATION; GENE INTERACTION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSTIMULATION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MALE HOMOSEXUAL; MONOCYTE; NATURAL KILLER CELL; PATHOGENESIS; PHAGOCYTE; PHAGOCYTOSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN POLYMORPHISM; RACE DIFFERENCE; STATISTICAL MODEL; T CELL DEPLETION;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; GENOTYPE; HUMANS; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; MUTATION, MISSENSE; POLYMORPHISM, GENETIC; RECEPTORS, IGG; RISK FACTORS;

EID: 84887134328     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.00573-13     Document Type: Article

References (67)

1. Datta K, Pirofski LA. 2006. Towards a vaccine for Cryptococcus neoformans: principles and caveats. FEMS Yeast Res. 6:525-536.
2. Jarvis JN, Lawn SD, Vogt M, Bangani N, Wood R, Harrison TS. 2009. Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin. Infect. Dis. 48:856-862.
3. Chayakulkeeree M, Perfect JR. 2006. Cryptococcosis. Infect. Dis. Clin. North Am. 20:507-544, v-vi.
4. Fleuridor R, Lyles RH, Pirofski L. 1999. Quantitative and qualitative differences in the serum antibody profiles of human immunodeficiency virus-infected persons with and without Cryptococcus neoformans meningitis. J. Infect. Dis. 180:1526-1535.
5. Deshaw M, Pirofski LA. 1995. Antibodies to the Cryptococcus neoformans capsular glucuronoxylomannan are ubiquitous in serum from HIV and HIV individuals. Clin. Exp. Immunol. 99:425-432.
6. Abadi J, Pirofski LA. 1999. Antibodies reactive with the cryptococcal capsular polysaccharide glucuronoxylomannan are present in sera from children with and without human immunodeficiency virus infection. J. Infect. Dis. 180:915-919.
7. Subramaniam K, French N, Pirofski LA. 2005. Cryptococcus neoformans-reactive and total immunoglobulin profiles of human immunodeficiency virus-infected and uninfected Ugandans. Clin. Diagn. Lab. Immunol. 12:1168-1176.
8. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. 2009. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 23:525-530.
9. Pappas PG. 2013. Cryptococcal infections in non-HIV-infected patients. Trans. Am. Clin. Climatol. Assoc. 124:61-79.
10. Pyrgos V, Seitz AE, Steiner CA, Prevots DR, Williamson PR. 2013. Epidemiology of cryptococcal meningitis in the US: 1997-2009. PLoS One 8:e56269. doi: 10.1371/journal.pone.0056269.
11. Singh N, Alexander BD, Lortholary O, Dromer F, Gupta KL, John GT, del Busto R, Klintmalm GB, Somani J, Lyon GM, Pursell K, Stosor V, Muñoz P, Limaye AP, Kalil AC, Pruett TL, Garcia-Diaz J, Humar A, Houston S, House AA, Wray D, Orloff S, Dowdy LA, Fisher RA, Heitman J, Wagener MM, Husain S. 2008. Pulmonary cryptococcosis in solid organ transplant recipients: clinical relevance of serum cryptococcal antigen. Clin. Infect. Dis. 46:e12-e18.
12. Subramaniam K, Metzger B, Hanau LH, Guh A, Rucker L, Badri S, Pirofski LA. 2009. IgM() memory B cell expression predicts HIVassociated cryptococcosis status. J. Infect. Dis. 200:244-251.
13. Rohatgi S, Pirofski LA. 2012. Molecular characterization of the early B cell response to pulmonary Cryptococcus neoformans infection. J. Immunol. 189:5820-5830.
14. Szymczak W, Davis M, Lundy S, Dufaud C, Olszewski M, Pirofski L. 2013. X-linked immunodeficient mice exhibit enhanced susceptibility to Cryptococcus neoformans infection. mBio 4:e00265-13. doi: 10.1128/ mBio.00265-13.
15. Chen LC, Goldman DL, Doering TL, Pirofski L, Casadevall A. 1999. Antibody response to Cryptococcus neoformans proteins in rodents and humans. Infect. Immun. 67:2218-2224.
16. Goldman DL, Khine H, Abadi J, Lindenberg DJ, Pirofski L, Niang R, Casadevall A. 2001. Serologic evidence for Cryptococcus neoformans infection in early childhood. Pediatrics 107:E66. doi: 10.1542/ peds.107.5.e66.
17. Mukherjee S, Lee SC, Casadevall A. 1995. Antibodies to Cryptococcus neoformans glucuronoxylomannan enhance antifungal activity of murine macrophages. Infect. Immun. 63:573-579.
18. Zhong Z, Pirofski LA. 1996. Opsonization of Cryptococcus neoformans by human anticryptococcal glucuronoxylomannan antibodies. Infect. Immun. 64:3446-3450.
19. Casadevall A, Pirofski L. 2005. Insights into mechanisms of antibodymediated immunity from studies with Cryptococcus neoformans. Curr. Mol. Med. 5:421-433.
20. Casadevall A, Cleare W, Feldmesser M, Glatman-Freedman A, Goldman DL, Kozel TR, Lendvai N, Mukherjee J, Pirofski LA, Rivera J, Rosas AL, Scharff MD, Valadon P, Westin K, Zhong Z. 1998. Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies. Antimicrob. Agents Chemother. 42:1437-1446.
21. Nimmerjahn F, Ravetch JV. 2006. Fcgamma receptors: old friends and new family members. Immunity 24:19-28.
22. Yuan R, Clynes R, Oh J, Ravetch JV, Scharff MD. 1998. Antibodymediated modulation of Cryptococcus neoformans infection is dependent on distinct Fc receptor functions and IgG subclasses. J. Exp. Med. 187:641-648.
23. Beenhouwer DO, Yoo EM, Lai CW, Rocha MA, Morrison SL. 2007. Human immunoglobulin G2 (IgG2) and IgG4, but not IgG1 or IgG3, protect mice against Cryptococcus neoformans infection. Infect. Immun. 75:1424-1435.
24. van Sorge NM, van der Pol WL, van de Winkel JG. 2003. FcgammaR polymorphisms: implications for function, disease susceptibility and immunotherapy. Tissue Antigens 61:189-202.
25. Meletiadis J, Walsh TJ, Choi EH, Pappas PG, Ennis D, Douglas J, Pankey GA, Larsen RA, Hamill RJ, Chanock S. 2007. Study of common functional genetic polymorphisms of FCGR2A, 3A and 3B genes and the risk for cryptococcosis in HIV-uninfected patients. Med. Mycol. 45: 513-518.
26. Hu XP, Wu JQ, Zhu LP, Wang X, Xu B, Wang RY, Ou XT, Weng XH. 2012. Association of Fc receptor IIB polymorphism with cryptococcal meningitis in HIV-uninfected Chinese patients. PLoS One 7:e42439. doi: 10.1371/journal.pone.0042439.
27. Lopez-Escamez JA, Saenz-Lopez P, Gazquez I, Moreno A, GonzalezOller C, Soto-Varela A, Santos S, Aran I, Perez-Garrigues H, Ibanez A, Lopez-Nevot MA. 2011. Polymorphisms of CD16A and CD32 Fcgamma receptors and circulating immune complexes in Meniere's disease: a casecontrol study. BMC Med. Genet. 12:2. doi: 10.1186/1471-2350-12-2.
28. Wu J, Edberg JC, Redecha PB, Bansal V, Guyre PM, Coleman K, Salmon JE, Kimberly RP. 1997. A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J. Clin. Invest. 100:1059-1070.
29. Kaslow RA, Ostrow DG, Detels R, Phair JP, Polk BF, Rinaldo CR, Jr. 1987. The multicenter AIDS cohort study: rationale, organization, and selected characteristics of the participants. Am. J. Epidemiol. 126: 310-318.
30. Poonia B, Kijak GH, Pauza CD. 2010. High affinity allele for the gene of FCGR3A is risk factor for HIV infection and progression. PLoS One 5:e15562. doi: 10.1371/journal.pone.0015562.
31. Armour KL, Smith CS, Clark MR. 2010. Expression of human FcgammaRIIIa as a GPI-linked molecule on CHO cells to enable measurement of human IgG binding. J. Immunol. Methods 354:20-33.
32. Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AE, de Haas M. 1997. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood 90:1109-1114.
33. Lipscomb MF, Alvarellos T, Toews GB, Tompkins R, Evans Z, Koo G, Kumar V. 1987. Role of natural killer cells in resistance to Cryptococcus neoformans infections in mice. Am. J. Pathol. 128:354-361.
34. Marr KJ, Jones GJ, Zheng C, Huston SM, Timm-McCann M, Islam A, Berenger BM, Ma LL, Wiseman JC, Mody CH. 2009. Cryptococcus neoformans directly stimulates perforin production and rearms NK cells for enhanced anticryptococcal microbicidal activity. Infect. Immun. 77: 2436-2446.
35. Houpt DC, Pfrommer GS, Young BJ, Larson TA, Kozel TR. 1994. Occurrences, immunoglobulin classes, and biological activities of antibodies in normal human serum that are reactive with Cryptococcus neoformans glucuronoxylomannan. Infect. Immun. 62:2857-2864.
36. Alvarez M, Casadevall A. 2006. Phagosome extrusion and host-cell survival after Cryptococcus neoformans phagocytosis by macrophages. Curr. Biol. 16:2161-2165.
37. García-Rodas R, Zaragoza O. 2012. Catch me if you can: phaocytosis and killing avoidance by Cryptococcus neoformans. FEMS Immunol. Med. Microbiol. 64:147-161.
38. Casadevall A. 2012. Amoeba provide insight into the origin of virulence in pathogenic fungi. Adv. Exp. Med. Biol. 710:1-10.
39. Ancuta P, Wang J, Gabuzda D. 2006. CD16 monocytes produce IL-6, CCL2, and matrix metalloproteinase-9 upon interaction with CX3CL1expressing endothelial cells. J. Leukoc. Biol. 80:1156-1164.
40. Eugenin EA, Osiecki K, Lopez L, Goldstein H, Calderon TM, Berman JW. 2006. CCL2/monocyte chemoattractant protein-1 mediates enhanced transmigration of human immunodeficiency virus (HIV) infected leukocytes across the blood-brain barrier: a potential mechanism of HIV-CNS invasion and NeuroAIDS. J. Neurosci. 26:1098-1106.
41. Ziegler-Heitbrock L. 2007. The CD14 CD16 blood monocytes: their role in infection and inflammation. J. Leukoc. Biol. 81:584-592.
42. Charlier C, Nielsen K, Daou S, Brigitte M, Chretien F, Dromer F. 2009. Evidence of a role for monocytes in dissemination and brain invasion by Cryptococcus neoformans. Infect. Immun. 77:120-127.
43. Pinheiro da Silva F, Aloulou M, Skurnik D, Benhamou M, Andremont A, Velasco IT, Chiamolera M, Verbeek JS, Launay P, Monteiro RC. 2007. CD16 promotes Escherichia coli sepsis through an FcR gamma inhibitory pathway that prevents phagocytosis and facilitates inflammation. Nat. Med. 13:1368-1374.
44. Lehrnbecher T, Foster CB, Zhu S, Leitman SF, Goldin LR, Huppi K, Chanock SJ. 1999. Variant genotypes of the low-affinity Fcgamma receptors in two control populations and a review of low-affinity Fcgamma receptor polymorphisms in control and disease populations. Blood 94: 4220-4232.
45. Brown EE, Fallin MD, Goedert JJ, Chen R, Whitby D, Foser CB, Lauria C, Alberg AJ, Messina A, Montella M, Rezza G, Vitale F, Chanock SJ, Kaposi Sarcoma Genetics Working Group. 2005. A common genetic variant in FCGR3A-V158F and risk of Kaposi sarcoma herpesvirus infection and classic Kaposi sarcoma. Cancer Epidemiol. Biomarkers Prev. 14: 633-637.
46. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H. 2002. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99:754-758.
47. Mailliard RB, Son YI, Redlinger R, Coates PT, Giermasz A, Morel PA, Storkus WJ, Kalinski P. 2003. Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function. J. Immunol. 171:2366-2373.
48. Buckner CM, Calderon TM, Willams DW, Belbin TJ, Berman JW. 2011. Characterization of monocyte maturation/differentiation that facilitates their transmigration across the blood-brain barrier and infection by HIV: implications for NeuroAIDS. Cell. Immunol. 267:109-123.
49. Forthal DN, Gabriel EE, Wang A, Landucci G, Phan TB. 2012. Association of Fc receptor IIIa genotype with the rate of HIV infection after gp120 vaccination. Blood 120:2836-2842.
50. Hajjeh RA, Conn LA, Stephens DS, Baughman W, Hamill R, Graviss E, Pappas PG, Thomas C, Reingold A, Rothrock G, Hutwagner LC, Schuchat A, Brandt ME, Pinner RW. 1999. Cryptococcosis: populationbased multistate active surveillance and risk factors in human immunodeficiency virus-infected persons. Cryptococcal Active Surveillance Group. J. Infect. Dis. 179:449-454.
51. Visnegarwala F, Graviss EA, Lacke CE, Dural AT, Johnson PC, Atmar RL, Hamill RJ. 1998. Acute respiratory failure associated with cryptococcosis in patients with AIDS: analysis of predictive factors. Clin. Infect. Dis. 27:1231-1237.
52. Monari C, Kozel TR, Paganelli F, Pericolini E, Perito S, Bistoni F, Casadevall A, Vecchiarelli A. 2006. Microbial immune suppression mediated by direct engagement of inhibitory Fc receptor. J. Immunol. 177: 6842-6851.
53. Niederer HA, Willcocks LC, Rayner TF, Yang W, Lau YL, Williams TN, Scott JA, Urban BC, Peshu N, Dunstan SJ, Hien TT, Phu NH, Padyukov L, Gunnarsson I, Svenungsson E, Savage CO, Watts RA, Lyons PA, Clayton DG, Smith KG. 2010. Copy number, linkage disequilibrium and disease association in the FCGR locus. Hum. Mol. Genet. 19:3282-3294.
54. Aitman TJ, Dong R, Vyse TJ, Norsworthy PJ, Johnson MD, Smith J, Mangion J, Roberton-Lowe C, Marshall AJ, Petretto E, Hodges MD, Bhangal G, Patel SG, Sheehan-Rooney K, Duda M, Cook PR, Evans DJ, Domin J, Flint J, Boyle JJ, Pusey CD, Cook HT. 2006. Copy number polymorphism in Fcgr3 predisposes to glomerulonephritis in rats and humans. Nature 439:851-855.
55. Fanciulli M, Norsworthy PJ, Petretto E, Dong R, Harper L, Kamesh L, Heward JM, Gough SC, de Smith A, Blakemore AI, Froguel P, Owen CJ, Pearce SH, Teixeira L, Guillevin L, Graham DS, Pusey CD, Cook HT, Vyse TJ, Aitman TJ. 2007. FCGR3B copy number variation is associated with susceptibility to systemic, but not organ-specific, autoimmunity. Nat. Genet. 39:721-723.
56. Bucasas KL, Pandya GA, Pradhan S, Fleischmann RD, Peterson SN, Belmont JW. 2009. Assessing the utility of whole-genome amplified serum DNA for array-based high throughput genotyping. BMC Genet. 10: 85. doi: 10.1186/1471-2156-10-85.
57. Maaroufi Y, Ahariz N, Husson M, Crokaert F. 2004. Comparison of different methods of isolation of DNA of commonly encountered Candida species and its quantitation by using a real-time PCR-based assay. J. Clin. Microbiol. 42:3159-3163.
58. Joshi D, Harris NB, Waters R, Thacker T, Mathema B, Krieswirth B, Sreevatsan S. 2012. Single nucleotide polymorphisms in the Mycobacterium bovis genome resolve phylogenetic relationships. J. Clin. Microbiol. 50:3859-3861.
59. Salanti G, Southam L, Altshuler D, Ardlie K, Barroso I, Boehnke M, Cornelis MC, Frayling TM, Grallert H, Grarup N, Groop L, Hansen T, Hattersley AT, Hu FB, Hveem K, Illig T, Kuusisto J, Laakso M, Langenberg C, Lyssenko V, McCarthy MI, Morris A, Morris AD, Palmer CN, Payne F, Platou CG, Scott LJ, Voight BF, Wareham NJ, Zeggini E, Ioannidis JP. 2009. Underlying genetic models of inheritance in established type 2 diabetes associations. Am. J. Epidemiol. 170:537-545.
60. Kuniholm MH, Gao X, Xue X, Kovacs A, Anastos K, Marti D, Greenblatt RM, Cohen MH, Minkoff H, Gange SJ, Fazzari M, Young MA, Strickler HD, Carrington M. 2011. Human leukocyte antigen genotype and risk of HIV disease progression before and after initiation of antiretroviral therapy. J. Virol. 85:10826-10833.
61. Subramaniam KS, Datta K, Quintero E, Manix C, Marks MS, Pirofski LA. 2010. The absence of serum IgM enhances the susceptibility of mice to pulmonary challenge with Cryptococcus neoformans. J. Immunol. 184: 5755-5767.
62. Bretscher MS. 1989. Endocytosis and recycling of the fibronectin receptor in CHO cells. EMBO J. 8:1341-1348.
63. Zhang Z, Morla AO, Vuori K, Bauer JS, Juliano RL, Ruoslahti E. 1993. The alpha v beta 1 integrin functions as a fibronectin receptor but does not support fibronectin matrix assembly and cell migration on fibronectin. J. Cell Biol. 122:235-242.
64. Binyamin L, Alpaugh RK, Hughes TL, Lutz CT, Campbell KS, Weiner LM. 2008. Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy. J. Immunol. 180:6392-6401.
65. Gong JH, Maki G, Klingemann HG. 1994. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 8:652-658.
66. Alvarez M, Burn T, Luo Y, Pirofski LA, Casadevall A. 2009. The outcome of Cryptococcus neoformans intracellular pathogenesis in human monocytes. BMC Microbiol. 9:51. doi: 10.1186/1471-2180-9-51.
67. Chow SK, Smith C, MacCarthy T, Pohl MA, Bergman A, Casadevall A. 2013. Disease-enhancing antibodies improve the efficacy of bacterial toxin-neutralizing antibodies. Cell Host Microbe 13:417-428.